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Genome-wide microRNA (miRNA) profiling of 82 glio-
blastomas demonstrated that miR-181d was inversely
associated with patient overall survival after correcting
for age, Karnofsky performance status, extent of resec-
tion, and temozolomide (TMZ) treatment. This associ-
ation was validated using the Cancer Genome Atlas
(TCGA) dataset (n 5 424) and an independent cohort
(n 5 35). In these independent cohorts, an association
of miR-181d with survival was evident in patients who
underwent TMZ treatment but was not observed in
patients without TMZ therapy. Bioinformatic analysis
of potential genes regulated by miR-181d revealed
methyl-guanine-methyl-transferase (MGMT) as a
downstream target. Indeed, transfection of miR-181d
downregulated MGMT mRNA and protein expression.
Furthermore, luciferase reporter assays and coprecipita-
tion studies showed a direct interaction between miR-
181d and MGMT 3′UTR. The suppressive effect of
miR-181d on MGMT expression was rescued by the
introduction of an MGMT cDNA. Finally, MGMT ex-
pression inversely correlated with miR-181d expression
in independent glioblastoma cohorts. Together, these
results suggest that miR-181d is a predictive biomarker
for TMZ response and that its role is mediated, in
part, by posttranscriptional regulation of MGMT.
Keywords: biomarker, glioblastoma, MGMT, miR-
181d, temozolomide.
G
lioblastoma is the most common form of
primary brain cancer1 and is well known for its
aggressive clinical course. A major advance in
glioblastoma therapy entailed the discovery that the
DNA alkylating agent temozolomide (TMZ) confers
survival benefit when combined with radiation
therapy.2,3 Despite data suggesting that only approxi-
mately 10% of the patients undergoing this therapy
achieve 5-year survival,2 all patients with glioblastoma
undergo the therapy because it is currently impossible
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to predict the subset of patients who will derive signifi-
cant therapeutic benefit. Thus, a major challenge in
neuro-oncology involves developing biomarkers that
will facilitate such prediction.
One important determinant of TMZ response in
patients with glioblastoma involves the DNA repair
protein methyl-guanine-methyl transferase (MGMT), a
protein responsible for repairing TMZ-induced DNA
damage.4 In several clinical series, high MGMT expres-
sion level was associated with TMZ therapy failure.5
Here, we identify miR-181d, a microRNA that is strong-
ly associated with survival in patients with glioblastoma
who underwent TMZ therapy. We demonstrate that the




This study was approved by the institutional review
boards of all participating hospitals, and written
informed consent was obtained from all patients. All
patients underwent surgical resection and had histologi-
cally confirmed glioblastomas. The characteristics of the
patients are listed in Supplementary material, Table S1.
Of importance, all patients underwent radiation
therapy. However, only a subset of patients was add-
itionally treated with TMZ. All tissue samples were
snap-frozen within 5 min of tumor removal. Samples
harboring ,80% tumor tissues were excluded. The
extent of resection was graded as gross total resection
(GTR) or non-GTR using MRIs obtained within 72 h
of surgical resection by 2 independent radiologists.
DNA, RNA, and miRNA Profiling
Isolation of DNA (QIAamp DNA Mini Kit; Qiagen) and
miRNA (mirVana miRNA Isolation kit; Ambion) from
tumor specimens was performed in accordance with
the manufacturer’s instructions. miRNA profiling was
performed using the Human v2.0 miRNA Expression
BeadChip (Illumina), and the microarray dataset was
deposited in GEO (accession number GSE25632) in ac-
cordance with MIAME guidelines. Quantitative reverse-
transcription polymerase chain reaction (qRT-PCR) was
performed using an ABI 7900 real-time PCR system
(Applied Biosystems) with the comparative Ct method
(for details, see Supplemental Methods). Pyrophosphate
sequencing was performed as previously described6 (for
details, see Supplemental Methods).
Statistical Analysis
Arrays were scanned with the Illumina BeadArray Reader
and analyzed using Illumina BeadStudio. Clinical correla-
tions were evaluated by x2 test or 1-way analysis of vari-
ance. The coefficient of variance (CV) was calculated
for each miRNA, and those with CV .0.8 were further
analyzed. Normalization of z-scores across samples was
performed, followed by using univariate Cox proportion-
al hazard regression analysis to estimate the significance
of the association for each miRNA expression with
overall survival. The P value for each miRNA was then
re-estimated by randomly assigning the survival time
and status (repeated 10 000 times) to obtain the P value
distribution. Permutation P value was then calculated
for each miRNA. After correction using the Benjamini-
Hochberg false discovery rate, 9 candidate miRNAs
were selected for further analysis. These miRNAs were
evaluated by Pearson correlation and Spearman correl-
ation analyses. miRNAs exhibiting statistically significant
association in all 3 analyses were then incorporated into a
Cox multivariate analysis that included Karnofsky per-
formance status (KPS), TMZ therapy, and extent of resec-
tion. Information with regard to the Cancer Genome
Atlas (TCGA) dataset and validation analysis can be
found in Supplemental Methods. All statistical analyses
were performed using Matlab 2009b, JMP (SAS
Institute), or GraphPad Prism (GraphPad Software).
Cells, Transfection, Immunoblotting, Luciferase
Assay, and Co-Precipitation Studies
A1207, T98G, LN340, and LN18 GBM cells were
grown in DMEM supplemented with 10% FBS and
1% Pen-Strep (Invitrogen) in a 5% CO2 incubator.
The cells were transfected with either miR-181d mimic
or control miRNA (Qiagen) using Hiperfect (Qiagen).
Cells were collected after 72 h. For RNA extraction,
total RNA isolation was performed using the
QiagenRNeasy kit (Qiagen). cDNAs were then gener-
ated using the iScript cDNA synthesis kit (Biorad).
MGMT and ACTB cDNA levels were assessed using
qRT-PCR (Supplemental Methods). Immunoblotting
was performed as previously described.7 Primary anti-
bodies used included anti-MGMT (Abcam, ab7045,
1:500) and a-tubulin (Sigma Aldrich, T9026, 1:3000).
Luciferase assays and coprecipitation studies were
performed as previously described8,9 (details in
Supplemental Methods). For the MGMT rescue experi-
ments, A1207, T98G, LN340, or LN18, glioblastoma
cells were cotransfected with combinations of control
vectors, miR-181d expression vectors (OriGene
Technologies), or MGMT cDNA expression vectors
(OriGene Technologies). MGMT expression was deter-
mined 72 h after transfection. Cell viability was deter-
mined either by trypan blue staining performed 72 h
after transfection or by clonogenic assays.
Results
miR-181d Level Is Inversely Correlated with Overall
Survival Among Patients with Glioblastoma
To identify miRNAs with potential prognostic or
predictive value, we profiled the miRNAs isolated from
82 clinically annotated glioblastoma samples collected
at Tiantan Hospital (termed the “discovery” set). All
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patients underwent radiation therapy, with a subset add-
itionally treated with TMZ. The clinical characteristics
of this cohort are shown in Supplementary material,
Table S1. The miRNA profiling data were first analyzed
using a univariate Cox proportional hazards model with
a correction for multiple comparisons. Candidates were
further tested for their associations with overall survival
using the Pearson’s and Spearman’s correlation
methods10 (Table 1a). Three miRNAs (miR-936,
miR-1238, and miR-181d) were consistently associated
with overall survival among patients with glioblastoma
by all 3 methods used.
Extent of resection (GTR versus subtotal resection)
and patient characteristics (KPS, age, sex) were also ana-
lyzed by univariate Cox regression analysis (Table 1b).
This analysis revealed that KPS, gross total resection,
and TMZ treatment were associated with overall
survival. We then performed a stepwise multivariate
Cox proportional hazards analysis incorporating KPS,
GTR, TMZ therapy, and the candidate miRNAs.
This analysis found that GTR, TMZ therapy, and
miR-181d remained significantly associated with sur-
vival. In contrast to previous reports,11 age and KPS
were not significantly associated with survival in our re-
gression analysis. We believe that this is attributable to
patient selection bias, because older patients or patients
with poor KPS rarely undergo resection in China and
would not be included in this cohort.
We then used the TCGA glioblastoma dataset
(n ¼ 424) to validate the association between miR-
181d and overall survival. We found that TCGA glio-
blastomas with higher than the median level of
miR-181d expression were associated with improved
survival relative to those with lower than the median
level of miR-181d (P ¼ .018) (Fig. 1A). To further
confirm this result, we performed qRT-PCR for
miR-181d in an independent cohort of 35 patients
with glioblastoma treated at Harbin Medical
University (termed the “validation set,” Supplementary
material, Table S1). Again, miR-181d expression was in-
versely correlated with overall survival in this validation
set (P ¼ .001) (Fig. 1B).
Having validated miR-181d in 3 independent
cohorts, we next investigated whether miR-181d consti-
tuted a prognostic or predictive biomarker by the uni-
variate Cox analysis. The association of miR-181d
with overall survival was evident in the TCGA and dis-
covery set patients who underwent TMZ treatment
(P ¼ .010 and .089, respectively). Such correlation was
not observed in patients without TMZ therapy. These
results suggest miR-181d as a predictive biomarker for
TMZ response (Fig. 1C). This analysis could not be
Table 1. miRNAs associated with survival in Tiantan cohort of 82 glioblastomas
(a)
Variable Univariate cox regression Pearson correlation Spearman correlation
Type P value HR Coefficient P-value Coefficient P-value
miR-181d Protective .004 0.654 0.241 .0293 0.244 .027
miR-936 Risky .001 1.468 –0.262 .0175 –0.261 .017
miR-1238 Risky .002 1.464 –0.245 .0262 –0.233 .035
miR-346 Risky .001 1.528 –0.263 .0175 ..05
miR-551a Risky .002 1.464 –0.232 .0356 ..05
miR-297 Risky .001 1.496 –0.226 .0410 ..05
miR-299-3p Risky .005 1.401 –0.242 .0287 ..05
miR-541* Risky .001 1.474 –0.248 .0246 ..05
miR-661 Risky .001 1.484 –0.260 .0185 ..05
(b)
Variable Univariate Cox Regression Multivariate Cox Regression
HR 95% CI P-value HR 95% CI P-Value
Sex 1.313 0.750–2.298 .34
Age 1.006 0.985–1.027 .59
KPS score 0.378 0.222–0.643 ,.001 0.769 0.371–1.595 .481
Gross total resection 0.427 0.251–0.726 .002 0.382 0.182–0.804 .011
Temozolomide 0.386 0.213–0.699 .002 0.416 0.219–0.793 .008
miR-181d 0.654 0.491–0.872 .004 0.808 0.659–0.969 .026
miR-936 1.468 1.173–1.836 .001 1.601 0.991–2.588 .055
miR-1238 1.464 1.153–1.857 .002 0.926 0.559–1.533 .765
Abbreviation: HR, hazard ratio.
Under the “Type” column, “Protective” denotes instances where the miRNA expression level is inversely correlated with overall survival
and “Risky” denotes instances where the miRNA expression level is correlated with overall survival. Coefficients of correlation by
Pearson’s or Spearman’s methods are as shown. P-values reaching statistical significance are shown in italics.
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performed in the validation set because of poorly docu-
mented TMZ treatment status.
MGMT Is a Direct Target of miR-181d
Bioinformatic analysis of potential miR-181d targets
revealed MGMT as a candidate (http://www.
microrna.org/microrna/home.do). Because of the critic-
al importance of MGMT in TMZ response,4 we
hypothesized that miR-181d downregulates MGMT,
thereby rendering glioblastomas more susceptible to
TMZ. Indeed, transfection of a miR-181d mimic into
the A1207 glioblastoma cell line caused decreased
MGMT mRNA and protein expressions (Fig. 2A). We
then tested whether MGMT is a direct target of
miR-181d using the pSiCheck-2 luciferase reporter con-
structs (Promega). The luciferase activity from the con-
struct containing the MGMT 3′UTR was reduced by
approximately 50% after transfection of miR-181d rela-
tive to a control miRNA (Fig. 2B, lanes 1 and 2). This
effect was not observed in the construct without the
MGMT 3′UTR. To further establish the MGMT
3′UTR as the direct target of miR-181d, we identified
2 predicted miR-181d binding (MRE) sites using
TargetScan 4.212 and cloned the 50 nucleotides contain-
ing each putative MRE into pSiCheck-2 vectors
(Fig. 2C). The luciferase activity from the constructs
containing either putative MRE was reduced by ap-
proximately 50% after transfection of miR-181d. This
suppressive effect was not observed with a control
miRNA. Of importance, mutating the putative MREs
abolished these effects (Fig. 2B, lanes 3–6). To demon-
strate a direct physical interaction between miR-181d
and MGMT mRNA, biotinylated miR-181d or control
miRNA was transfected into A1207 cells, and
mRNA-biotinylated miRNA complexes were pulled
down using streptavidin beads.8 We found an approxi-
mately 2.5-fold enrichment of MGMT transcript in the
miR-181d pull-down relative to the control miRNA
(Fig. 2D). Together, these results provide evidence that
miR-181d directly interacts with MGMT transcript to
downregulate its expression.
MGMT Transcript Level Inversely Correlates
with miR-181d Level
Given the results suggesting that miR-181d post-
transcriptionally regulates MGMT, we anticipated an
Fig. 1. miR-181d inversely correlates with overall survival. (A) miR-181d inversely correlated with overall survival in the TCGA database.
Blue: higher than median expression. Red: lower than median expression. (B) miR-181d correlated with overall survival in an
independent cohort of 35 patients as assessed by qRT-PCR. Blue: higher than median expression. Red: lower than median expression.
(C) Correlation of miR-181d with survival after stratification of TMZ treatment status.
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inverse correlation between miR-181d expression level
and MGMT transcript level in glioblastoma specimens.
We tested this hypothesis by analyzing 223 glioblast-
omas from the TCGA dataset (see Supplemental
Methods).13 The analysis indeed revealed an inverse re-
lationship between the miR-181d expression level and
the MGMT transcript level, albeit not one reaching stat-
istical significance (P ¼ .09, R2 ¼ 0.09) (Fig. 3A). We
reasoned that the MGMT promoter methylation could
affect MGMT transcript level5,14 in addition to
miR-181d regulation. We therefore selected glioblast-
omas with unmethylated MGMT promoter from the
TCGA database using the previously established cri-
teria.13 In the 159 specimens with unmethylated
MGMT promoter, the MGMT transcript level was in-
versely correlated with the miR-181d level (P ¼ .004,
R2 ¼ 0.13) (Fig. 3B). To validate this observation, we
analyzed the MGMT promoter methylation using an in-
dependent set of 20 glioblastomas. Of the 20 tumors, 9
showed heavy MGMT promoter methylation. All
methylated tumors exhibited low or undetectable levels
of MGMT mRNA. In the remaining 11 specimens, the
MGMT transcript level was inversely correlated with
miR-181d expression (P ¼ .04, R2 ¼ 0.62) (Fig. 3C).
miR-181d–Induced TMZ Sensitivity Can Be Restored
by Expression of MGMT cDNA
Our data suggested that miR-181d downregulates
MGMT expression by direct binding of its 3′UTR. It
follows that MGMT expression from a cDNA lacking
the 3′UTR should be resistant to the effect of
miR-181d. Furthermore, miR-181d–induced TMZ sen-
sitivity should be restored by the introduction of an
MGMT cDNA. Indeed, suppression of MGMT expres-
sion by miR-181d (Fig. 4A, lane 5) was restored by intro-
duction of a construct expressing MGMT cDNA
(Fig. 4A, lane 6). In addition, the TMZ sensitivity
observed when miR-181d was introduced into the
A1207 glioblastoma line (Fig. 4B, lane 8) was abolished
by the expression of MGMT by a cDNA construct
(Fig. 4B, lane 9). This result was confirmed using 3
independent glioblastoma lines: T98G, LN340, and
LN18 (Fig. 4).
Discussion
The critical role of MGMT as a cellular determinant of
TMZ response is well established in model organisms
Fig. 2. miR-181d downregulates MGMT expression. (A) Transfection of miR-181d suppressed MGMT mRNA (top panel) and protein
expression in the A1207 glioblastoma cell line (bottom panel). For qRT-PCR, MGMT mRNA was normalized either to b-actin mRNA (shown
here) or U6 rRNA (with comparable results, data not shown). For the Western blotting, a-tubulin was used as the loading control.
(B) miR-181d binding sites in the MGMT 3′UTR suppressed luciferase expression in the presence of miR-181d. (C) Predicted miR-181d
binding sites in the MGMT 3′UTR. (D), miR-181d physically interacts with MGMT transcript. b-actin was used as an internal control.
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spanning the entire evolutionary ladder.15,16 Here, we
offer the first evidence that MGMT is posttranscription-
ally regulated by miR-181d. Our transfection experi-
ments, luciferase reporter assays, and coprecipitation
studies suggested that miR-181d directly interacts with
the MGMT 3′UTR to regulate MGMT at a posttran-
scriptional level. In support of this hypothesis, the
expression level of miR-181d was inversely correlated
with the MGMT transcript level in glioblastoma
specimens. Furthermore, the suppressive effect of
miR-181d on MGMT expression (and related TMZ sen-
sitivity) can be reversed by expression of MGMT cDNA.
Finally, high expression of miR-181d (and, thus, lower
MGMT) was associated with improved overall survival
in 3 independent cohorts totaling .500 patients with
glioblastoma. Of importance, the results were robustly
reproducible using high-quality glioblastoma specimens
(.80% viable tumors) collected from different sites and
using distinct profiling platforms and statistical
methods.
From a biomarker perspective, our findings suggest 2
novel discovery strategies. First, it is known that each
miRNA can modulate the expression of hundreds of
gene transcripts.17 The resultant phenotype is likely to
be the aggregate effect of many altered transcripts. In
this context, we believe that miR-181d regulated other
gene transcripts (apart from MGMT) that contributed
to the prognostic or predictive value of miR-181d, and
it would be of interest to identify such transcripts.
Second, the modest correlation between miR-181d and
MGMT (Fig. 3) suggests the existence of other
MGMT-regulating miRNAs. These miRNAs, such as
miR-181d, may serve as predictive biomarkers for
TMZ response.
Previous studies have suggested that MGMT is both a
predictive biomarker for TMZ therapy4 and a prognos-
tic marker for patients with glioblastoma.5,18 The pre-
dictive value of MGMT can be related largely to its
DNA repair capacity.4 It is difficult to explain why
MGMT expression level was correlated with survival
among patients who did not undergo TMZ
therapy.5,18 It seems likely that MGMT may participate
in the repair of endogenously occurring, toxic DNA
damage typically found in glioblastoma cells.7 If one
adopts this paradigm, one would anticipate that
miR-181d, through its regulation of MGMT, has both
predictive and prognostic value. Our study showed
that the association of miR-181d with survival was
most evident in patients treated with TMZ, suggesting
that miR-181d is a predominantly predictive biomarker.
We attribute this observation to the fact that miRNAs
typically act to fine tune the expression level of their
targets19 rather than function as an on-off switch. We
speculate that the residual MGMT expression (Fig. 2A)
may be sufficient for the repair of endogenous DNA
damage but insufficient to repair the excess damage
caused by TMZ therapy.
A potential clinical application of our finding relates
to the use of MGMT promoter methylation as a glio-
blastoma biomarker. MGMT promoter methylation is
inversely correlated with MGMT expression14,20 and is
associated with TMZ response.5 A major limitation of
MGMT promoter methylation–based diagnosis,
however, is that it fails to account for other mechanisms
regulating MGMT expression, such as posttranscrip-
tional regulation. Indeed, a subset of patients with
unmethylated MGMT promoter glioblastomas responds
favorably to TMZ.2,3 We propose that MGMT-
regulating miRNAs, such as miR-181d, may be useful
Fig. 3. miR-181d expression level inversely correlates with MGMT
mRNA level. (A) Correlation between miR-181d and MGMT
transcript level in 223 TCGA patients with characterized MGMT
promoter, MGMT mRNA level, and miR181-d level (P ¼ .09,
R2 ¼ 0.09). (B) Correlation of miR-181d and MGMT transcript
level in 159 patients with unmethylated MGMT promoter (P ¼
.004, R2 ¼ 0.13). Relative abundance of MGMT and miR-181d is
plotted on the x- and y-axes. (C) Inverse correlation between
miR-181d and MGMT transcript level in an independent set of
11 glioblastomas (P ¼ .04, R2 ¼ 0.62). Expression levels of
miR-181d and MGMT were assessed by qRT-PCR. Relative
abundance of each is plotted on the x- and y-axes.
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for patient selection in this context. This thesis awaits
prospective validation in future clinical trials.
Supplementary Material
Supplementary material is available at Neuro-Oncology
Journal online (http://neuro-oncology.oxfordjournals.
org/).
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